Seong-Wook Kim1, Misun Seo2, Duk-Soo Kim3, Moonkyung Kang4, Yeon-Soo Kim5, Hae-Young Koh6, Hee-Sup Shin7. 1. Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon 305-811, and the Department of Neuroscience, Korea University of Science and Technology, Daejeon, Republic of Korea. 2. Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul, and the Department of Neuroscience, Korea University of Science and Technology, Daejeon, Republic of Korea. 3. Department of Anatomy, College of Medicine, Soonchunhyang University, Cheonan-Si, Republic of Korea. 4. Indang Institute of Molecular Biology, Inje University, Seoul, Republic of Korea. 5. Indang Institute of Molecular Biology, Inje University, and the Department of Smart Foods and Drugs, Inje University, Seoul, Republic of Korea. 6. Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul and the Department of Neuroscience, Korea University of Science and Technology, Daejeon, Republic of Korea. 7. Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon 305-811 and the Department of Neuroscience, Korea University of Science and Technology, Daejeon, Republic of Korea.
Abstract
BACKGROUND: Decreased expression of phospholipase C-β1 (PLC-β1) has been observed in the brains of patients with schizophrenia, but, to our knowledge, no studies have shown a possible association between this altered PLC-β1 expression and the pathogenesis of schizophrenia. Although PLC-β1-null (PLC-β1(-/-)) mice exhibit multiple endophenotypes of schizophrenia, it remains unclear how regional decreases in PLC-β1 expression in the brain contribute to specific behavioural defects. METHODS: We selectively knocked down PLC-β1 in the medial prefrontal cortex (mPFC) using a small hairpin RNA strategy in mice. RESULTS: Silencing PLC-β1 in the mPFC resulted in working memory deficits, as assayed using the delayed non-match-to-sample T-maze task. Notably, however, other schizophrenia-related behaviours observed in PLC-β1-/- mice, including phenotypes related to locomotor activity, sociability and sensorimotor gating, were normal in PLC-β1 knockdown mice. LIMITATIONS: Phenotypes of PLC-β1 knockdown mice, such as locomotion, anxiety and sensorimotor gating, have already been published in our previous studies. Further, the neural mechanisms underlying the working memory deficit in mice may be different from those in human schizophrenia. CONCLUSION: These results indicate that PLC-β1 signalling in the mPFC is required for working memory. Importantly, these results support the notion that the decrease in PLC-β1 expression in the brains of patients with schizophrenia is a pathogenically relevant molecular marker of the disorder.
BACKGROUND: Decreased expression of phospholipase C-β1 (PLC-β1) has been observed in the brains of patients with schizophrenia, but, to our knowledge, no studies have shown a possible association between this altered PLC-β1 expression and the pathogenesis of schizophrenia. Although PLC-β1-null (PLC-β1(-/-)) mice exhibit multiple endophenotypes of schizophrenia, it remains unclear how regional decreases in PLC-β1 expression in the brain contribute to specific behavioural defects. METHODS: We selectively knocked down PLC-β1 in the medial prefrontal cortex (mPFC) using a small hairpin RNA strategy in mice. RESULTS: Silencing PLC-β1 in the mPFC resulted in working memory deficits, as assayed using the delayed non-match-to-sample T-maze task. Notably, however, other schizophrenia-related behaviours observed in PLC-β1-/- mice, including phenotypes related to locomotor activity, sociability and sensorimotor gating, were normal in PLC-β1 knockdown mice. LIMITATIONS: Phenotypes of PLC-β1 knockdown mice, such as locomotion, anxiety and sensorimotor gating, have already been published in our previous studies. Further, the neural mechanisms underlying the working memory deficit in mice may be different from those in humanschizophrenia. CONCLUSION: These results indicate that PLC-β1 signalling in the mPFC is required for working memory. Importantly, these results support the notion that the decrease in PLC-β1 expression in the brains of patients with schizophrenia is a pathogenically relevant molecular marker of the disorder.
Authors: Jonghan Shin; Daesoo Kim; Riccardo Bianchi; Robert K S Wong; Hee-Sup Shin Journal: Proc Natl Acad Sci U S A Date: 2005-12-05 Impact factor: 11.205
Authors: Hao-Yang Tan; Steven Sust; Joshua W Buckholtz; Venkata S Mattay; Andreas Meyer-Lindenberg; Michael F Egan; Daniel R Weinberger; Joseph H Callicott Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: Christoph Kellendonk; Eleanor H Simpson; H Jonathan Polan; Gaël Malleret; Svetlana Vronskaya; Vanessa Winiger; Holly Moore; Eric R Kandel Journal: Neuron Date: 2006-02-16 Impact factor: 17.173
Authors: Jacqueline N Crawley; Thomas Chen; Amit Puri; Richard Washburn; Timothy L Sullivan; Joanna M Hill; Nancy B Young; Jessica J Nadler; Sheryl S Moy; Larry J Young; Heather K Caldwell; W Scott Young Journal: Neuropeptides Date: 2007-04-08 Impact factor: 3.286
Authors: Anthony M Chomyk; Christina Volsko; Ajai Tripathi; Sadie A Deckard; Bruce D Trapp; Robert J Fox; Ranjan Dutta Journal: Sci Rep Date: 2017-08-18 Impact factor: 4.379